Investment opportunities
Six regulated manufacturing tiers, each with anchored national demand and a defined incentive pathway.
Tier 1
Essential Medicines Manufacturing
$15M – $80M
20–40% - import substitution opportunity
- MSD framework contracts with 15% local price preference
- WHO-PQ and GMP support through the TMDA 60-day fast-track
- 20–40% import substitution headroom in national demand
Tier 2
API & Excipients Manufacturing
$50M – $200M
Zero - EAC production capacity today
- First-mover position: zero EAC API capacity exists today
- Feedstock for Tier 1 formulation plants inside the same zone
- Bagamoyo greenfield site available for USD 50M+ strategic projects
Tier 3
Vaccines & Biologics
$80M – $300M
Zero - domestic human vaccine capacity
- National priority: zero domestic human vaccine capacity
- Green-lane approvals and government-to-government offtake channels
- Regional pooled procurement access across EAC and SADC
Tier 4
Small-Volume Parenterals
$5M – $40M
None - ampoules/vials manufactured in Tanzania
- Purpose-zoned sterile sub-zone B3 (45 acres) ready for allocation
- High-volume injectable demand in national procurement
- Compact CAPEX with fast TMDA registration pathway
Tier 5
Medical Devices & Consumables
$5M – $40M
>90% - currently imported
- Over 90% import dependence across devices and consumables
- 50-acre purpose-built Medical Devices zone (Zone A)
- 15% MSD price preference on qualifying product lines
Tier 6
Diagnostics & IVDs
$10M – $50M
~99% - currently imported
- Approximately 99% of IVDs currently imported
- Dedicated Diagnostics zone plus Lab Complex infrastructure
- Same duty exemptions and fast-track as pharma manufacturers